While more VCs have created venture incubators to nurture early concepts into full-fledged start-ups, they are aligned more on the need to incubate than on how best to do it.
Indeed, a collection of VCs who spoke to BioCentury all think about incubation in different ways. Nevertheless, the group has managed to launch an impressive list of biotechs building potentially disruptive technologies by proactively sourcing or creating their own opportunities and culturing them internally.
The list includes the likes of Flagship Pioneering’s Moderna Therapeutics Inc., which has raised about $1 billion in venture rounds since its founding in 2010 to generate a pipeline of mRNA-based therapies.
Flagship was the earliest of the group to adopt the incubator model, forming Flagship VentureLabs in 2000.
The more recent spate of new incubators dates to 2011, when Versant Ventures established Inception Sciences Inc.. Since then, Versant has established two others, Highline Therapeutics and Blueline BioScience, and Avalon Ventures and 5AM Ventures have also joined the club (see “Venture Incubators”).
Several VCs have formed dedicated incubators to foster early-stage projects not yet ready for series A, which take a variety of forms and have different specialties. They broadly fall into the categories of internal incubators used by the firms to nurture opportunities sourced internally or externally, and regional incubators tied to academic institutions, often with specific pharma partners. The incubators also vary by whether they have physical lab space, a model dubbed “brick-and-mortar,” or whether they operate virtually and source experiments through CROs and academic partners. PureTech Health plc and Accelerator Corp. operate entirely by incubation, and unlike the other firms, do not create companies outside this model. Source: VC and company websites; interviews
|Year||VC||Incubator||Purpose||Model||Pharma partners||Newcos launched|
|2000||Flagship Pioneering||VentureLabs||Explore biological white spaces; disruptive platforms||Brick-and-mortar||None||19|
|2003||Accelerator Corp.||N/A||Single targets; broad platforms||Brick-and-mortar||None||15|
|2005||PureTech Health plc||N/A||New modalities for neurology, immunology, gastrointestinal diseases||Brick-and-mortar||None||12|
|2011||Versant Ventures||Inception Sciences Inc.||Small molecule drug discovery||Brick-and-mortar||None||6|
|2013||Avalon Ventures||COI Pharmaceuticals Inc.||Single target build-to-buys with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK); Single assets at lead-optimization stage; disruptive platforms||Brick-and-mortar||GlaxoSmithKline plc||12|
|2013||Versant Ventures||Blueline Bioscience||Biologics drug discovery||Virtual||None||1|
|2015||5AM||4:59 initiative||Disruptive platforms||Virtual||None||2|
|2016||Versant Ventures||Highline Therapeutics||Single targets; broad platforms||Hybrid||None||1|
|2014||OrbiMed||FutuRx||Translate Israel's academic science||Brick-and-mortar||Johnson & Johnson (NYSE:JNJ); Takeda Pharmaceutical Co. Ltd. (Tokyo:4502)||9|
|2015||Sofinnova||BiovelocITA||Translate Italy's academic science||Virtual||None||1|
|2016||Deerfield; Bay City Capital||Bridge Medicines||IND-enabling studies for three universities in New York, N.Y.||Virtual||Takeda Pharmaceutical Co. Ltd.||0|
While all take different incubation strategies, the consensus